Analysts Set Collegium Pharmaceutical, Inc. (COLL) Target Price at $22.20

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has received a consensus recommendation of “Hold” from the eight brokerages that are currently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $22.20.

COLL has been the subject of a number of recent analyst reports. Zacks Investment Research lowered shares of Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Wednesday, May 10th. Needham & Company LLC decreased their target price on shares of Collegium Pharmaceutical from $28.00 to $25.00 and set a “buy” rating for the company in a research report on Thursday, May 11th. Jefferies Group LLC reiterated a “buy” rating and issued a $22.00 target price (down previously from $24.00) on shares of Collegium Pharmaceutical in a research report on Thursday, May 11th. Janney Montgomery Scott reiterated a “buy” rating and issued a $25.00 target price on shares of Collegium Pharmaceutical in a research report on Monday, June 12th. Finally, ValuEngine upgraded shares of Collegium Pharmaceutical from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd.

Several institutional investors have recently bought and sold shares of COLL. Eventide Asset Management LLC raised its stake in Collegium Pharmaceutical by 3.7% in the first quarter. Eventide Asset Management LLC now owns 2,153,612 shares of the specialty pharmaceutical company’s stock worth $21,665,000 after buying an additional 75,861 shares in the last quarter. Sectoral Asset Management Inc raised its stake in Collegium Pharmaceutical by 41.4% in the second quarter. Sectoral Asset Management Inc now owns 1,808,750 shares of the specialty pharmaceutical company’s stock worth $22,627,000 after buying an additional 529,503 shares in the last quarter. Macquarie Group Ltd. raised its stake in Collegium Pharmaceutical by 37.1% in the second quarter. Macquarie Group Ltd. now owns 1,118,691 shares of the specialty pharmaceutical company’s stock worth $13,995,000 after buying an additional 302,892 shares in the last quarter. Morgan Stanley raised its stake in Collegium Pharmaceutical by 684.8% in the first quarter. Morgan Stanley now owns 885,268 shares of the specialty pharmaceutical company’s stock worth $8,906,000 after buying an additional 772,464 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in Collegium Pharmaceutical by 7.8% in the first quarter. Vanguard Group Inc. now owns 806,539 shares of the specialty pharmaceutical company’s stock worth $8,113,000 after buying an additional 58,398 shares in the last quarter. Institutional investors own 83.13% of the company’s stock.

Shares of Collegium Pharmaceutical (NASDAQ COLL) traded up 2.97% during mid-day trading on Friday, hitting $10.04. 300,660 shares of the company traded hands. The firm has a 50-day moving average price of $11.08 and a 200 day moving average price of $11.37. Collegium Pharmaceutical has a 52-week low of $7.37 and a 52-week high of $20.55. The firm’s market cap is $296.84 million.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported ($0.72) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.81) by $0.09. The firm had revenue of $3.56 million during the quarter, compared to analyst estimates of $4.07 million. Collegium Pharmaceutical had a negative net margin of 1,319.39% and a negative return on equity of 93.73%. Equities research analysts anticipate that Collegium Pharmaceutical will post ($3.00) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This news story was posted by BBNS and is the sole property of of BBNS. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://baseballnewssource.com/markets/analysts-set-collegium-pharmaceutical-inc-coll-target-price-at-22-20/1565398.html.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Will 2017 MLB Season End with No 20-Game Winner?
Will 2017 MLB Season End with No 20-Game Winner?
Cleveland Indians Winning Streak Snapped at 22
Cleveland Indians Winning Streak Snapped at 22
Tigers Player Might Play All Nine Positions During Same Game
Tigers Player Might Play All Nine Positions During Same Game
Fans Kicked Out of Fenway Park After Racist Banner Hung on Green Monster
Fans Kicked Out of Fenway Park After Racist Banner Hung on Green Monster
Dodgers End Losing Streak at 11 Behind Ace Clayton Kershaw
Dodgers End Losing Streak at 11 Behind Ace Clayton Kershaw
Cleveland Indians Winning Streak Reaches 18
Cleveland Indians Winning Streak Reaches 18


Leave a Reply

 
© 2006-2017 BBNS.